Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial

Author:

Zheng Jinping1,Zhong Nanshan1,Wang Changzheng2,Wei Li Ping3,Zhou Xiang Dong4,Zhao Li5,Dong Yuan Ya6,He Bei7,Wu Bin8,Du Xin9,Song Jie9,Lipson David A.1011

Affiliation:

1. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

2. Xinqiao Hospital, Third Military Medical University, Chongqing, China

3. Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China

4. Xinan Hospital, Third Military Medical University, Chongqing, China

5. Shengjing Hospital of China Medical University, Shenyang, China

6. Respiratory Department, The Second Hospital of Hebei Medical University, Shijazhuang, China

7. Peking University Third Hospital, Beijing, China

8. Affiliated Hospital, Guangdong Medical University, Zhanjiang, China

9. GSK, Shanghai, China

10. GSK, Collegeville, PA, USA

11. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Publisher

Informa UK Limited

Subject

General Medicine

Reference29 articles.

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2019 report); 2019.

2. World Health Organization. The top 10 causes of death. 2018. [cited 2019 Jul 30]. Available from: http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death.

3. Projections of Global Mortality and Burden of Disease from 2002 to 2030

4. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study

5. Patterns and management of chronic obstructive pulmonary disease in urban and rural China: a community-based survey of 25 000 adults across 10 regions

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3